Table 1.
Immune checkpoint molecules tested for therapeutic effects in leishmaniasis.
| Disease |
Biological system |
Reference | |||||
|---|---|---|---|---|---|---|---|
| Visceral leishmaniasis | Cutaneous leishmaniasis | Diffused cutaneous leishmaniasis | Mucocutaneous leishmaniasis | Human | Preclinical | ||
| IL-10 | Y | Y | Y | Y | (15, 24, 26, 27, 41–45) | ||
| PD-1 | Y | Y | Y | Y | Y | (38, 40, 46–50) | |
| PDL-1/2 | Y | (49) | |||||
| CTLA-4 | Y | Y | Y | (34–37, 51, 52) | |||
| OX40 | Y | Y | Y | (37, 53, 54) | |||
| CD40 | Y | Y | Y | (36, 55–57) | |||
| CD28 | Y | Y | (36) | ||||
| CD80/86 | Y | Y | (58–61) | ||||
| ICOS | Y | Y | (62) | ||||
Y, indicates immune checkpoint molecule tested in the disease indicated.